29 Oct PAA Members Can Prebook NEW MenQuadfi Now
Posted at 14:14h in News, Uncategorized
Sanofi Pasteur has announced that MenQuadfi™ (Meningococcal [Groups A, C, Y, W] Conjugate Vaccine) has been approved by the FDA for active immunization for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y.
The development of MenQuadfi and the high seroresponse generated in clinical trials illustrates Sanofi Pasteur’s continued commitment and leadership as a longstanding pioneer in meningococcal vaccines. Please see below links to documents with additional information on MenQuadfi:
- MenQuadfi Flashcard – contains information on studies in which MenQuadfi was compared head-to-head with other licensed quadrivalent meningococcal vaccines
- MenQuadfi Prescribing Information – contains important clinical and product information
PAA members linked to our Sanofi contract can pre-book now for April delivery at a discounted price. Log in to learn more.